Xiaoling Li, MD, is the senior medical manager, oncology for Fortrea, based in Wuhan, China. Xiaoling has more than 15 years of experiences in industry, including hospital, pharmaceutical companies and CRO, focused on providing drug development expertise to the medical strategy and execution of the programs, performing medical and safety monitoring on the projects. Xiaoling earned her master degree of Hematology from Tongji Medical College of Huazhong University of Science & Technology in 2008. She joined our company in Jan 2021.

Vitaliy Solskyy, MD, PhD, is an OB/GYN doctor by background (Institute of Pediatrics, Obstetrics and Gynecology, AMS of Ukraine) and holds a PhD in the field of gynecological endocrinology. He has authored around 40 scientific publications, did participate in numerous OB/GYN forums around the world, along with presenting at several big national and international congresses. Dr. Solskyy has joined Fortrea (formerly Labcorp/Covance) in 2015 and overall has more than 20 years of clinical research experience running global studies, 15 of which in management roles of increasing responsibility. He has a passion for women’s health with the dedication of his career to this field and has participated in numerous Phase II-IV studies in a variety of women’s health indications, including last eight years predominantly managing and overseeing several large women’s health programs.

Vikas Mohan Sharma, MD, joined Fortrea in December 2023 and serves as its Global Head of Neuroscience and Ophthalmology therapeutic areas. He is a recognized industry leader with more than 23 years of experience in healthcare and clinical development, known for his expertise in research ethics and patient safety. 

Dr. Sharma has held various leadership roles in healthcare, CROs and the biopharmaceutical industry and is considered a key opinion leader in the field of drug development. He leads and collaborates on various industry, consortia and non-governmental efforts to advance progress in precision psychiatry, digital biomarkers and the use of technologies to address healthcare access and “last mile” challenges. 

In his most recent role with Boehringer Ingelheim, Dr. Sharma was responsible for the end-to-end clinical development strategy and execution of early and late-stage products, as well as leading global clinical development, medical affairs and scientific relations teams spanning multiple therapeutic areas. With 16 years of clinical experience in psychiatry and as an investigator in CNS trials, Dr. Sharma has a track record of success in developing and executing first-in-class, “blue ocean” and “beyond the pill” product strategies for pharmacological as well as digital assets. He is known to champion early investment in biomarker development and has a passion for bringing the right stakeholders together. 

Dr. Sharma also serves an independent ethics expert with the European Research Council and other non-governmental organizations. He is passionate about helping children with special needs and volunteers for this cause by sharing his time and expertise. He earned his MD in Psychological Medicine from Seth Gordhandas Sunderdas Medical College (GSMC) and the King Edward Memorial (KEM) Hospital in Mumbai, India.

Victor Angélico, MD, is a Senior Medical Director for Fortrea, based in Paris, France. He provides clinical and medical expertise to project teams and other Fortrea departments to advance clients’ drug development programs. Dr. Angélico performs medical monitoring on assigned projects; reviews protocols, case report forms and other data and materials, and contributes to the scientific leadership of the Oncology area at Fortrea with a special focus in early phase clinical studies and hematological malignancies. 

Dr. Angélico is board-certified in Internal Medicine and Oncology with 16 years in the clinic and has significant medical and pharmaceutical expertise with 14 years of experience in the pharmaceutical industry. Before his current position, he served as Senior Medical Officer for Chiltern, France and as Medical Director at IQVIA France. Dr. Angelico joined our company in January 2019.

Verena brings more than 25 years of clinical research experience, with 17 years in global project management across Phase I to Phase IV. She has more than 16 years of experience at Fortrea and offers extensive operational background in respiratory indications, including sinusitis, pharyngitis, bronchitis and pneumonia. 

In her previous role as Director of Project Management, Verena provided oversight for several international studies in Asthma and Chronic Obstructive Pulmonary Disease (COPD). She currently provides functional support from a strategic perspective to our teams.

Veerle Van De Velde, MD, currently works as a Global Project physician in the IGM therapeutic area (TA). In this role, she is responsible for overseeing global trials, mostly in rare respiratory indications. Tasks include protocol development and feedback, team training, site communication, data review and interpretation, DMC and adjudication support, data review meetings, assistance with CSR writing. Drawing on more than 25 years of experience in the pharmaceutical and CRO industry, Dr. Van De Velde gets involved in business development activities and may also act in a consultant role as part of a molecular development team. 

Dr. Veerle Van De Velde obtained her medical degree in 1995 and worked as a sub-investigator in the Respiratory Department of the University Hospital in Ghent. She started her career in drug Development in the respiratory area in a hospital setting and spent four years doing clinical research in Phase II, III, and IV trials in asthma, COPD, respiratory infections and pulmonary oncology under the guidance of Prof R.A. Pauwels. As a sub-I, Dr. Van De Velde was responsible for recruiting patients, administering patients’ project-specific procedures, compiling CRF data, collecting adverse event information, and timely reporting to sponsors and ethics committees. She has experience in both basic and clinical research, with expertise in rare respiratory disease and IPF. Later, she worked as a project physician in a variety of indications and was responsible for overseeing global clinical trials, medical data review and team training both internally and externally.

Valery Chatikine, MD, PhD, is a medical oncologist, board certified by University of Paris XI and Cancer Research Center of the Russian Academy Medical Science, with more than 10 years medical oncology clinical practice. He is experienced in oncology drug development Phase I-III studies for multiple solid tumors and selected hematologic malignancies with small, large molecules (Immuno-Oncology), ADCs, T cells and NK cells in solid tumors, glioblastoma and lymphoma with FDA and EMA relevant IND/NDAs/BLA submission and approval involvement. Dr. Chatikine is well published with more than 40 publications in peer-reviewed journals (Journal of Clinical Oncology, American Journal of Clinical Oncology, European Journal of Clinical Oncology and Cancer Letters). He is an active member of American Society of Clinical Oncology (ASCO) and Society for Neuro-Oncology (SNO). He joined our company in April 2022.

Dr. Korchak has more than 23 years of drug development industry experience across broad indication of neuroscience, supporting studies for small molecules, biologics and cell and gene therapies. Her expertise extends from early phase development through late phase/post-marketing studies in capacity of investigator, operational leader and head of clinical development of autologous cell therapy at a biotech company. As an investigator, Dr. Korchak held various COA certifications, e.g., EDSS, ADAS-cog, MMSE and CDR. Her expertise encompasses neurodegenerative, acute and rare neurology and various psychiatry diseases.

Tanya has over 26 years of experience with Fortrea (formerly Labcorp, Covance and Chiltern), including monitoring, global project management, delivery director oversight and strategic planning and growth. Her clinical research experience includes a broad range of therapeutic experience with the last 15 years specifically focused on ophthalmology. Tanya’s ocular experience covers front and back of the eye indications, inherited retinal and ocular rare diseases across phase I-IV and medical device studies as well as ocular cell and gene therapies. 

Her extensive delivery background, coupled with her ocular experience supports both internal and external stakeholders in the strategic development of a reduced burden approach, as well as an efficient and successfully executed ocular trial. 

Tanya is passionate about ensuring the priorities of a clinical trial are 1) to reduce the burden across all stakeholders 2) a realistic, common-sense approach and 3) at the end of the day, we all do what we do for the patients!

Susanne Schmidt, MD, PhD, is a Senior Medical Director of Fortrea’s Rare Diseases, Advanced Therapies and Pediatrics Team (RAPT). She is a Board-Certified pediatrician with more than 14 years of clinical experience across multiple therapeutic areas including pediatric gastroenterology and rare diseases. 

Dr. Schmidt has 10 years of industry experience in the CRO environment, which includes projects in pediatrics, rare diseases and advanced therapies (gene therapy, RNAi) across many indications and all phases of development. She also has broad experience supporting projects across all pediatric age groups including premature neonates.